|
Affymax Announces Close of Common Stock
Offering and Exercise of Underwriters' Overallotment Option
PALO ALTO, Calif., Nov 24, 2009 (BUSINESS WIRE) -- Affymax, Inc.
(Nasdaq:AFFY) today announced the closing of its underwritten
public offering of 4,726,027 shares of its common stock, which
includes the full exercise of the underwriter's overallotment
option of 616,438 shares. The net proceeds to the company after
deducting underwriting discounts and commissions and estimated
offering expenses are approximately $80.0 million.
Cowen and Company, LLC and Lazard Capital Markets LLC were joint
book-runners on the offering and RBC Capital Markets Corporation
and Robert W. Baird & Co. Incorporated were co-managers for the
offering.
The securities described above were offered by the company
pursuant to a shelf registration statement which was filed with
the Securities and Exchange Commission (SEC) on October 2, 2009
and became effective on October 22, 2009. A prospectus
supplement and the accompanying base prospectus describing the
terms of the offering have been filed with the SEC and form part
of the effective Registration Statement.
Copies of the final prospectus supplement and accompanying base
prospectus relating to this offering can be obtained at the
SEC's website at
http://www.sec.gov or from Cowen and Company, LLC c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department or by calling
(631) 254-7106 or from Lazard Capital Markets LLC at 30
Rockefeller Plaza, 60th Floor, New York, NY 10020 or by calling
(800) 542-0970.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company committed to
developing novel drugs to improve the treatment of serious and
often life-threatening conditions.
Contact
Affymax, Inc.
Sylvia Wheeler
650-812-8861
Executive Director, Corporate Communications
|
